初诊2型糖尿病患者血清C反应蛋白水平及通心络干预的影响

目的探讨初诊2型糖尿病患者血清C反应蛋白(CRP)水平及通心络胶囊干预的影响。方法选择初诊2型糖尿病患者130例为观察组,均测定诊断时的血清CRP,控制血糖12周,然后分为血糖控制良好组(A组)和血糖控制不良组(B组),第13周开始给予口服通心络(2粒,3次/d)12周,观察其对不同血糖水平患者血清CRP水平的影响;正常体检者60例作为对照组。结果(1)观察组血清CRP水平(4.80 mg/L±1.74 mg/L)明显高于对照组(2.76 mg/L±0.64 mg/L),P<0.01;(2)随着观察组血糖的控制,CPR水平下降至(4.06±1.28)mg/L,其下降幅度与血糖下降幅度呈正相关(r=0.382 4,P< 0.01),但仍高于对照组;(3)通心络可使观察组中A组和B组的CRP水平降低,A组(0.38±0.03)mg/L 与B组(0.56±0.05)mg/L比较,差异有非常显著意义(P<0.01)。但对血糖无影响。结论通心络可降低2型糖尿病患者的CRP水平,减轻2型糖尿患者的炎症状念,因此对2型糖尿病及并发症的发生、发展有积极的预防作用。

Serum C-reactive protein levels in patients with type 2 diabetes mellitus and the effect of Tongxinluo capsule intervention

Objective To investigate the serum C-reactive protein (CRP) levels in patients with type 2 diabetes mellitus (DM) and the effect of Tongxinluo capsule intervention. Methods 130 patients with type 2 DM who were diagnosed in first visit examination were chosen as treatment group. The patients' serum CRP concentrations were tested when they were firstly diagnosed, then they were treated by controlling blood glucose for 12 weeks. After that they were divided into group A (blood glucose coutrolled well) and group B (blood glucose coutrolled badly) .All the patients were treated by Tongxinluo capsule for another 12 weeks. Meanwhile the changes of serum CRP concentration in patients with different blood glucose levels were observed. 60 normal subjects were chosen as control group. Results (1) The serum CRP concentration (4.80 mg/L ± 1.74 mg/L) in treatment group was significantly higher than that in control group (2.76 mg/L ± 0.64 mg/L, P < 0. 01); (2) The serum CRP concentration in treatment group was gradually decreased to (4.06± 1.28)mg/L with controlling blood glucose, which was positively correlated with blood glucose (r = 0.382 4, P < 0.01) .however, which was still higher than that in control group; (3)Tongxin-luo capsule could decrease the serum CRP concentration in group A (0.38±0.03)mg/L and group B (0.56±0.05) mg/L, P < 0.01, especially in group B,but which didn't affect blood glucose. Conclusion Tongxinluo capsule can reduce the serum CRP concentration and inflammation state in patients with type 2 DM,which plays an active role in preventing the occurrence and development of type 2 DM and complications.